Global Fund Results Report reveals COVID-19 devastating impact on HIV, TB and malaria programs.

Agreement between non-profit product development partnership and multinational pharmaceutical company will expand access to new TB drug.

Tuberculosis (TB) is a wily old killer, one of the deadliest infectious diseases in history and one of the few that naturally infects only humans. Researchers at Weill Cornell Medicine have been pursuing treatments for tuberculosis caused by Mycobacterium tuberculosis (Mtb) since the 1950s, and the program continues to excel at explaining TB’s mysteries and pushing toward more effective therapies.

Robert Koch, a founding father of microbiology, used hands-on experiments in the 1800s to find the bacteria behind three of history's deadliest diseases.

Take a short survey and help evaluate the first 10 years of the Global TB CAB!

On 24 September 2021, the Permanent Mission of the Russian Federation to the United Nations (UN) and the World Health Organization will co-host a special UN General Assembly virtual side event to review progress towards reaching global TB targets, advance multisectoral action and accountability, and discuss preparations for the 2023 UN High-Level Meeting on TB.

Use of an add-on dry powder inhaler (DPI) containing fixed doses of isoniazid, rifampicin, pyrazinamide, and levofloxacin did not increase sputum conversion in patients receiving standard oral therapy for pulmonary tuberculosis (TB); however, the combined antibiotic DPI did result in greater cough relief, according to study findings published in Pulmonary Pharmacology & Therapeutics.

On 23 September 2021, RESIST-TB will host a webinar to present the results of the recently-completed NeXT clinical trial for multidrug-resistant TB.

Glycemic changes may play an important role in response to treatment among patients with tuberculosis who do not have diabetes, according to data published in the American Journal of Respiratory Critical Care Medicine.

The International Journal of Tuberculosis and Lung Disease (IJTLD) is the official publication of the International Union Against Tuberculosis and Lung Disease (The Union).